Live Breaking News & Updates on Angiotensin System

Stay updated with breaking news from Angiotensin system. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Travere Therapeutics (TVTX) Reports Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI Demonstrating Long-Term Kidney Function Preservation

Travere Therapeutics (TVTX) Reports Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI Demonstrating Long-Term Kidney Function Preservation
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Brad Rovin , Nivi Nehra , Naomi Eichenbaum , Deric Dube , Travere Therapeutics Inc , Clinical Research Management , Division For Nephrology , European Union , European Medicines Agency , Committee For Medicinal Products Human Use , Ohio State University Center , Exchange Commission , Corporate Communications , Travere Therapeutics , New Drug Application , Medical Director , Conditional Marketing Authorization , Medicinal Products , Human Use , Important Safety , Endothelin Receptor Antagonists , Upper Limit , Fetal Toxicity , Kidney Injury , Angiotensin System ,

Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan

FILSPARI® achieved a clinically meaningful difference vs. irbesartan in eGFR total slope [p= 0.058] and eGFR chronic slope [p=0.037]. Patients treated with FILSPARI over two years exhibited one of. ....

United States , Brad Rovin , Nivi Nehra , Deric Dube , Naomi Eichenbaum , Clinical Research Management , Travere Therapeutics Inc , Corporate Communications , Exchange Commission , Division For Nephrology , European Union , Ohio State University Center , European Medicines Agency , Committee For Medicinal Products Human Use , New Drug Application , Medical Director , Conditional Marketing Authorization , Medicinal Products , Human Use , Important Safety , Endothelin Receptor Antagonists , Upper Limit , Fetal Toxicity , Kidney Injury , Angiotensin System , Acid Reducing Agents ,

Travere Therapeutics Announces Presentations of Abstracts at the 60th European Renal Association (ERA) Congress 2023

Travere Therapeutics Announces Presentations of Abstracts at the 60th European Renal Association (ERA) Congress 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United Kingdom , Jula Inrig , Naomi Eichenbaumvice , Nivi Nehravice , Exchange Commission , Company Quarterly Report On Form , Travere Therapeutics Inc , Corporate Communications , United Kingdom Radar Registry , Kidney Failure , Treatment Effects , Iga Nephropathysession , Iga Nephropathylocation , Proteinuria Reduction , Interim Analysissession , Long Term Outcomes , Short Term Proteinuria Datasession , Iga Nephropathy Pathwaylocation , Syndrome Natural History , Radar Registry , Variant Type , Small Patients , Big Datalocation , Their Relationship , Time Averaged Proteinuriasession , Moderated Orals ,

Travere Therapeutics Announces Presentations of Abstracts at the 60th European Renal Association (ERA) Congress 2023

SAN DIEGO, June 08, 2023 Travere Therapeutics, Inc. today announced that the Company and its collaborators will present nine abstracts, including the interim analysis from the ongoing Phase 3. | June 10, 2023 ....

United Kingdom , Nivi Nehra , Naomi Eichenbaum , Jula Inrig , Travere Therapeutics Inc , Exchange Commission , Company Quarterly Report On Form , Corporate Communications , United Kingdom Radar Registry , Kidney Failure , Treatment Effects , Proteinuria Reduction , Long Term Outcomes , Short Term Proteinuria , Iga Nephropathy , Syndrome Natural History , Radar Registry , Variant Type , Small Patients , Their Relationship , Moderated Orals , Adjusted Indirect Comparison , Adult Patients , Rare Kidney Diseases , Care Partners Study , Natural History ,